Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Satoko Ito, Karthik Chetlapalli, Daniel Wang, Kunal C Potnis, Rhys Richmond, Harlan Krumholz, Alfred I Lee, Adam Cuker, George Goshua

Blood blood.2024025176.

https://doi.org/10.1182/blood.2024025176

Published: 2024

Includes: Supplemental data

Journal Articles

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D. Bona, Adam Cuker, George Goshua

Blood (2024) 143 (22): 2332–2335.

https://doi.org/10.1182/blood.2024024209

Published: 2024

Includes: Supplemental data

Journal Articles

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Daniel Wang, Satoko Ito, Christina Waldron, Ayesha Butt, Ellen Zhang, Harlan M. Krumholz, Hanny Al-Samkari, George Goshua

Blood (2023) 142 (Supplement 1): 2312.

https://doi.org/10.1182/blood-2023-185340

Published: 2023

Journal Articles

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Christina Waldron, Satoko Ito, Daniel Wang, Giri Viswanathan, Ayesha Butt, George Goshua

Blood (2023) 142 (Supplement 1): 2317.

https://doi.org/10.1182/blood-2023-189957

Published: 2023

Journal Articles

Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Satoko Ito, Karthik Chetlapalli, Kunal C Potnis, Rhys Richmond, Daniel Wang, Alfred I Lee, George Goshua

Blood (2023) 142 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2023-188063

Published: 2023

Journal Articles

Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura

Cecily Allen, Satoko Ito, Ayesha Butt, Adriana Purcell, Rhys Richmond, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 368.

https://doi.org/10.1182/blood-2023-184927

Published: 2023

Journal Articles

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Satoko Ito, Kunal C Potnis, Cecily Allen, Rhys Richmond, Christina Waldron, Giri Viswanathan, Robert D Bona, George Goshua

Blood (2023) 142 (Supplement 1): 492.

https://doi.org/10.1182/blood-2023-190420

Published: 2023

Journal Articles

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

George Goshua, Satoko Ito, Karthik Chetlapalli, Kunal C Potnis, Cecelia Calhoun, Lakshmanan Krishnamurti, Harlan M. Krumholz, Ankur Pandya

Blood (2023) 142 (Supplement 1): 490.

https://doi.org/10.1182/blood-2023-191072

Published: 2023

Journal Articles

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

Christina Waldron, Satoko Ito, Daniel Wang, Cecily Allen, Giri Viswanathan, Robert D Bona, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 3698.

https://doi.org/10.1182/blood-2023-188018

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States

Satoko Ito, Daniel Wang, Adriana Purcell, Karthik Chetlapalli, Alfred I Lee, Adam Cuker, George Goshua

Blood (2023) 142 (Supplement 1): 2316.

https://doi.org/10.1182/blood-2023-187270

Published: 2023

Journal Articles

Consecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit

Cecily Allen, Michael Streiff, Rakhi P P. Naik, Melissa Knauert, George Goshua

Blood (2023) 142 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2023-184891

Published: 2023

Journal Articles

Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Blood (2023) 142 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2023-185232

Published: 2023

Journal Articles

Summiting thrombotic hazards in glioma

George Goshua, Alfred Ian Lee

Blood (2023) 141 (11): 1245–1246.

https://doi.org/10.1182/blood.2022019020

Published: 2023

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease

George Goshua, Ronald G. Hauser, Chris Tormey, Ankur Pandya, Jeanne E. Hendrickson

Blood (2022) 140 (Supplement 1): 2147–2148.

https://doi.org/10.1182/blood-2022-169099

Published: 2022

Journal Articles

Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

George Goshua, Cecelia Calhoun, Vivien Cheng, Lyndon James, Andrea Luviano, Lakshmanan Krishnamurti, Ankur Pandya

Blood (2022) 140 (Supplement 1): 1395–1396.

https://doi.org/10.1182/blood-2022-157460

Published: 2022

Journal Articles

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 319–321.

https://doi.org/10.1182/blood-2022-158465

Published: 2022

Journal Articles

Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial Thresholds

Ayesha Butt, Alfred I Lee, George Goshua

Blood (2022) 140 (Supplement 1): 1621–1622.

https://doi.org/10.1182/blood-2022-170003

Published: 2022

Journal Articles

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Jan Philipp Bewersdorf, Kishan K. Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Scott F. Huntington, Amer M. Zeidan

Blood (2022) 139 (11): 1766–1770.

https://doi.org/10.1182/blood.2021014401

Published: 2022

Includes: Supplemental data

NARROW

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States

Longitudinal Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic Telangiectasia with Moderate-to-Severe Bleeding

Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy

Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States

Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura

Equitable Care for Severe Hemophilia_A: Distributional Cost-Effectiveness of Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in Patients with Severe Hemophilia_A in the United States

Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States

Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Cost-Effectiveness of Sutimlimab Versus Standard-of-Care in Transfusion Dependent Patients with Primary Cold Agglutinin Disease in the United States

Consecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit

Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

Summiting thrombotic hazards in glioma

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease

Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Cost-Effectiveness of Caplacizumab without First-Line Therapeutic Plasma Exchange Vs. Standard-of-Care for Patients with Immune Thrombotic Thrombocytopenic Purpura: Setting Future Clinical Trial Thresholds

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only